Soluble CD40 ligand inhibits the growth of non-Hodgkin's lymphoma cells through the JNK signaling pathway

被引:2
|
作者
Feng, Zhongxin [1 ,2 ,3 ,4 ]
Wang, Jishi [1 ,2 ,3 ,4 ]
机构
[1] Guizhou Med Univ, Clin Med Sch, Guiyang 550004, Guizhou, Peoples R China
[2] Guizhou Med Univ, Dept Hematol, Affiliated Hosp, 9 Beijing St, Guiyang 550004, Guizhou, Peoples R China
[3] Guizhou Prov Hematopoiet Stem Cell Transplantat C, Guiyang 550004, Guizhou, Peoples R China
[4] Key Lab Hematol Dis Diagnost & Treatment Ctr, Guiyang 550004, Guizhou, Peoples R China
关键词
sCD40L; Raji; CA46; proliferation; JNK; non-Hodgkin' s lymphoma; CROSS-LINKING; T-CELLS; EXPRESSION; APOPTOSIS; CANCER; ACTIVATION; CARCINOMA; PROTEIN; KINASE; RESISTANCE;
D O I
10.3892/ol.2020.12318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incidence of non-Hodgkin's lymphoma (NHL) has been increasing annually and has become a serious threat to human health. However, the pathogenesis of NHL remains unclear. The present study aimed to investigate the effect of soluble CD40 ligand (sCD40L) on NHL cells and its underlying mechanism. Cell Counting kit-8 assay and flow cytometry apoptosis experiments were conducted to investigate the effects of sCD40L on cell proliferation and apoptosis. Western blotting was performed to detect the protein expression levels of BAX, Bcl-2, ERK, p-ERK, JNK, p-JNK, p38, p-p38 and c-JUN. The results of the present study demonstrated that exogenous sCD40L significantly inhibited the proliferation and promoted the apoptosis of Raji and CA46 cells. Additionally, exogenous sCD40L promoted the apoptosis of lymphoma cells by activating the JNK signaling pathway.
引用
收藏
页数:7
相关论文
共 50 条
  • [21] Enhancement of binding activity of soluble human CD40 to CD40 ligand through incorporation of an isoleucine zipper motif
    He, XH
    Xu, LH
    Liu, Y
    ACTA PHARMACOLOGICA SINICA, 2006, 27 (03) : 333 - 338
  • [22] Fas ligand expression in nodal non-Hodgkin's lymphoma
    Mullauer, L
    Mosberger, I
    Chott, A
    MODERN PATHOLOGY, 1998, 11 (04) : 369 - 375
  • [23] The Soluble Factor from Oral Cancer Cell Lines Inhibits Interferon-γ Production by OK-432 via the CD40/CD40 Ligand Pathway
    Ohe, Go
    Kudo, Yasusei
    Kamada, Kumiko
    Mouri, Yasuhiro
    Takamaru, Natsumi
    Kudoh, Keiko
    Kurio, Naito
    Miyamoto, Youji
    CANCERS, 2021, 13 (13)
  • [24] Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells
    Voorzanger-Rousselot, N
    Favrot, MC
    Blay, JY
    BLOOD, 1998, 92 (09) : 3381 - 3387
  • [25] Inhibition of Terminal Differentiation of B Cells Mediated by CD27 and CD40 Involves Signaling through JNK
    Satpathy, Shuchismita
    Shenoy, Gautam N.
    Kaw, Sheetal
    Vaidya, Tushar
    Bal, Vineeta
    Rath, Satyajit
    George, Anna
    JOURNAL OF IMMUNOLOGY, 2010, 185 (11): : 6499 - 6507
  • [26] Collagen synthesis by human intestinal fibroblasts (HIF) is modulated by T-cells through the CD40/CD40 ligand (CD40L) pathway
    Vogel, JD
    Majors, A
    Sturm, A
    West, GA
    Chakravarti, S
    Fiocchi, C
    GASTROENTEROLOGY, 2001, 120 (05) : A135 - A135
  • [27] Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors
    Gazitt, Y
    Shaughnessy, P
    Liu, Q
    JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (01): : 167 - 176
  • [28] CD40 INHIBITS REPLICATION OF HEPATITIS C VIRUS BY JNK ACTIVATION INDEPENDENTLY OF THE INTERFERON PATHWAY
    Rau, S. J.
    Hildt, E.
    Blum, H. E.
    Fischer, R.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S325 - S325
  • [29] Excess bone marrow mast cells constitutively express CD154 (CD40 ligand) in Waldenstrom's macroglobulinemia and may support tumor cell growth through CD154/CD40 pathway
    Tournilhac, O
    Santos, DD
    Branagan, A
    Hunter, Z
    Manning, R
    Tai, YT
    Kutok, JL
    Munshi, N
    Anderson, KC
    Treon, SP
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 571S - 571S
  • [30] Serum CD44 in non-Hodgkin's lymphoma
    Ristamäki, R
    Joensuu, H
    Jalkanen, S
    LEUKEMIA & LYMPHOMA, 1999, 33 (5-6) : 433 - 440